N-(3-chloropropyl)-2-methoxyphenylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(3-chloropropyl)-2-methoxyphenylamine
• 英文别名: N-(3-chloropropyl)-2-methoxyaniline
• 化学式: C₁₀H₁₄ClNO
• 分子量: 199.68
• InChiKey: MOQOYRGEECUJTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-chloropropyl)-2-methoxyphenylamine 在 硼烷四氢呋喃络合物 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 N-(2-Chloroethyl)-N-(3-chloropropyl)-2-methoxyaniline
  参考文献：
  名称：

  EP1736467

  摘要：

  公开号：
• 作为产物：
  描述：

  邻甲氧基苯胺 、 1-溴-3-氯丙烷 在 potassium carbonate 作用下， 以 丁酮 为溶剂， 反应 8.0h， 以69.3%的产率得到N-(3-chloropropyl)-2-methoxyphenylamine
  参考文献：
  名称：

  Synthesis, docking and pharmacological evaluation of novel indole based potential atypical antipsychotics

  摘要：

  A series of substituted indole derivatives have been synthesized and the target compounds evaluated for atypical antipsychotic activity in apomorphine induced mesh climbing and stereotypy assays in mice. The compounds 11 and 12 have emerged as important lead compounds showing potential atypical antipsychotic profile. In silico (docking studies) have been carried out to postulate a hypothetical binding model for the target compounds with respect to the dopaminergic D-2 and 5-HT2A receptors. Theoretical ADME profiling of the compounds based on selected physicochemical parameters has suggested an excellent compliance with Lipinski's rules. The potential of these compounds to penetrate the blood brain barrier (log BB) was computed through an online software program and the values obtained for the compounds suggest good potential for brain permeation. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.09.020

文献信息

• Novel piperidine derivative
  申请人：Ban Hitoshi

  公开号：US20070078120A1

  公开（公告）日：2007-04-05

  The invention provides a compound of the following formula (1): wherein m, n, and p are independently an integer of 0-4, provided 3≦m+n≦8; X is nitrogen atom or a group of the formula: C—R 15 ; Y is a substituted or unsubstituted aromatic group, etc.; R 15 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc., or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.

  本发明提供了以下式(1)的化合物：其中m，n和p分别是0-4的整数，满足3≦m+n≦8；X是氮原子或式：C—R15的基团；Y是取代或未取代的芳香基团等；R15，R1，R2，R3，R4，R5，R6和R7是氢原子，取代或未取代的烷基等；Z是氢原子，氰基等，或其前药，或其药学上可接受的盐，具有增强LDL受体表达的作用，并且可用作治疗高脂血症，动脉粥样硬化等药物。
• Novel Sulfonamide derivative
  申请人：Ban Hitoshi

  公开号：US20080096922A1

  公开（公告）日：2008-04-24

  A compound of the formula (1): wherein m, n and p is independently an integer of 0 to 4 with the proviso that 3≦m+n≦8; X is the formula: NR 4 , etc.; R 1 , R 3 and R 4 are a substituted or unsubstituted aryl group, etc.; R 2 is a hydrogen atom, etc.; a, b, c, d, e and f are a hydrogen atom or a substituted or unsubstituted alkyl group, etc.; Y is the formula: —SO 2 —, etc.; and Z is an oxygen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt of the same has an activity of potentiating an expression of a low density lipoprotein receptor and thus is useful as an agent for treating hyperlipidemia or arteriosclerosis.

  公式（1）的化合物： 其中，m，n和p分别为0至4的整数，但须满足3≦m+n≦8；X为公式：NR4等；R1，R3和R4为取代或未取代的芳基基团等；R2为氢原子等；a，b，c，d，e和f为氢原子或取代或未取代的烷基基团等；Y为公式：—SO2—等；Z为氧原子等；或其前体药物或其药学上可接受的盐具有增强低密度脂蛋白受体表达的活性，因此可用作治疗高脂血症或动脉硬化的药物。
• Substituierte Tetrahydropyrimidinonderivate, Verfahren zu ihrer Herstellung und Herbizide, die diese Derivate als Wirkstoffe enthalten
  申请人：NIHON TOKUSHU NOYAKU SEIZO K.K.

  公开号：EP0058868A1

  公开（公告）日：1982-09-01

  Die Erfindung betrifft neue substituierte Tetrahydropyrimidinon-Derivate der allgemeinen Formel worin die Gruppen Ar gleich oder verschieden sein können und jeweils die in der Beschreibung angegebene Bedeutung besitzen, mehrere Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide.

  本发明涉及通式中的新的取代的四氢嘧啶酮衍生物，通式中的基团 Ar 可以相同或不同，各自具有描述中给出的含义，本发明还涉及其制备的几种工艺及其作为除草剂的用途。
• NOVEL PIPERIDINE DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1679069A1

  公开（公告）日：2006-07-12

  The invention provides a compound of the following formula (1): wherein m, n, and p are independently an integer of 0 - 4, provided 3 ≤ m + n ≤ 8; X is nitrogen atom or a group of the formula: C-R15; Y is a substituted or unsubstituted aromatic group, etc.; R15, R1, R2, R3, R4 , R5, R6 and R7 are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc., or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.

  本发明提供了下式（1）的化合物： 其中m、n和p独立地为0-4的整数，条件是3≤m+n≤8；X为氮原子或式中的基团：C-R15；Y 是取代或未取代的芳香基等；R15、R1、R2、R3、R4、R5、R6 和 R7 是氢原子、取代或未取代的烷基等；Z 是氢原子、氰基等、 或其原药或其药学上可接受的盐，具有增强低密度脂蛋白受体表达的作用，可作为治疗高脂血症、动脉粥样硬化等的药物。
• NOVEL SULFONAMIDE DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1736467A1

  公开（公告）日：2006-12-27

  A compound of the formula (1): wherein m, n and p is independently an integer of 0 to 4 with the proviso that 3 ≦ m + n ≦ 8; X is the formula: NR4, etc.; R1, R3 and R4 are a substituted or unsubstituted aryl group, etc.; R2 is a hydrogen atom, etc.; a, b, c, d, e and f are a hydrogen atom or a substituted or unsubstituted alkyl group, etc.; Y is the formula: -SO2-, etc.; and Z is an oxygen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt of the same has an activity of potentiating an expression of a low density lipoprotein receptor and thus is useful as an agent for treating hyperlipidemia or arteriosclerosis.

  式 (1) 的化合物： 其中 m、n 和 p 独立地为 0 至 4 的整数，但 3 ≦ m + n ≦ 8；X 为式中的NR4等；R1、R3和R4是取代或未取代的芳基等；R2是氢原子等；a、b、c、d、e和f是氢原子或取代或未取代的烷基等；Y是式：-SO2-等：-SO2-等；Z是氧原子等； 或其原药或其药学上可接受的盐具有增强低密度脂蛋白受体表达的活性，因此可用作治疗高脂血症或动脉硬化的药物。